BOSTON, April 12, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (NASDAQ:CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced poster presentations on CTX-009, the Company's bispecific DLL4/VEGF-A antibody, at the Cholangiocarcinoma Foundation (CCF) 2024 Annual Conference to be held at the Salt Palace Convention Center in Salt Lake City, Utah from April 17–19, 2024.
Presentation Details:
Poster Title: Introduction of CTX-009 and COMPANION-002 Study
Authors: Katie Kelley, Scott Paulson, Mitesh Borad, Lipika Goyal, Nilofer Azad, Minori Rosales & Milind Javle
Poster Title: Survey of CTX-009 Patient Selection Hypotheses Using Real World Biliary Tract Cancer Data
Authors: Minori Rosales, Thomas Schuetz, Anna Gifford, Nicole Gampp, Alberto Visintin, Rachael Duffy, Diana Albu, Patricia Gonzalez, Kelly Ocasio, Karin Herrera, Kris F. Sachsenmeier
A copy of the presentation materials can be accessed on the News & Events section under "Presentations" of the Company's website at www.compasstherapeutics.com once the presentation has concluded.
About Compass Therapeutics
Compass Therapeutics, Inc. is a clinical-stage oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. ...